Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69268 | 0.90 | PTPN11 (0.69) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL10412465 | 0.86 | PTPN11 (0.60) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL254229 | 0.85 | PTPN11 (0.59) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL1535874 | 0.84 | PTPN11 (0.63) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL19513816 | 0.83 | PTPN11 (0.51) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL19102737 | 0.82 | PTPN11 (0.57) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL1105504 | 0.82 | TSHR (0.67) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL3013267 | 0.82 | PTPN11 (0.57) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL22466110 | 0.82 | PTPN11 (0.57) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL16140276 | 0.82 | TDP1 (0.77) | PTPN11CA1CA2TDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373900-A1 | CYCLOPROPENIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) | 2023-11-23 | — | — | US | disclosed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009007396-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373900-A1 | CYCLOPROPENIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE | DHPS, CYP11B2, PIN1 | PTPN11 1898/4885CA1 1596/4885CA2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.